Stock Alert: Intra-Cellular Therapies Shares Surge 82% In Early Trade

(RTTNews) - Shares of Intra-Cellular Therapies Inc. (ITCI) are rising over 82% in pre-market today, after the company reported positive topline results from its Phase 3 clinical trial (Study 402) evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

The stock has been trading in the range of $6.75 - $43.56 for the past one year, and closed Tuesday's trade at $18.43, up 38 cents or 2.11%. ITCI is currently trading at $33.64, up $15.21 or 82.53% in the pre-market session.